After a dosing amendment, the issues were cleared up in the patients. Now, a data safety monitoring board has cleared the dose-escalation phase of the trial, according to a statement from Ultragenyx issued Wednesday. RELATED: Ultragenyx pauses antisense trial after patients lose ability to walk Ultragenyx said that the first four patients have received multiple doses without any treatment-related serious adverse events—specifically, no cases of lower extremity weakness have been observed. Shares of California-based Ultragenyx rose more than 5% on the news to $88.07 apiece as of 10:57 a.m. ET on Wednesday. The companies have also begun to evaluate the clinical response from the treatment, although those data were not reported in the update. The main goal of the trial is to assess safety and efficacy based on a measure of improvement in overall disease severity and change at day 58, before increased dosing. The trial includes several groups with patients ranging in age from 4 to 18 years old.